Crispr Therapeutics AG

CRISPR Therapeutics announced robust second quarter 2026 financial results, highlighted by significant revenue growth for CASGEVY and progress across its diverse pipeline of gene-editing therapies.

CRISPR Therapeutics shareholders approved the 2026 Stock Option and Incentive Plan and amended the company's articles of association at the 2026 Annual General Meeting.

CRISPR Therapeutics announced its first quarter 2026 financial results, highlighting $43 million in CASGEVY revenue and progress across its diverse pipeline of gene-editing therapies.

CRISPR Therapeutics AG successfully closed its private offering of $600 million in 1.7308% Convertible Senior Notes due 2031, bolstering its financial position for general corporate purposes.

CRISPR Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting continued progress across its diverse gene-editing pipeline and global uptake of CASGEVY.

CRISPR Therapeutics AG announced significant progress across its cardiovascular, autoimmune, immuno-oncology, and regenerative medicine programs, including positive clinical data and new collaborations.

CRISPR Therapeutics AG filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its gene-editing therapies, including CASGEVY, alongside financial performance and strategic updates.

CRISPR Therapeutics AG reports Q1 2026 results with increased cash reserves, ongoing R&D investment, and progress in gene-editing therapies.

CRISPR Therapeutics reported an increased net loss in Q3 2025, driven by higher collaboration expenses, while highlighting positive Phase 1 data for CTX310 and ongoing commercialization of CASGEVY.

CRISPR Therapeutics AG reported a significantly increased net loss for Q2 2025, driven by higher operating expenses including a substantial acquired R&D charge, despite ongoing clinical progress and commercialization efforts for CASGEVY.

CRISPR Therapeutics reports a net loss for Q1 2025, but highlights progress in clinical trials and commercialization of CASGEVY.

CRISPR Therapeutics reports a net loss of $85.9 million for the third quarter of 2024, while highlighting progress in its gene editing programs and collaborations.

CRISPR Therapeutics AG reported a significant increase in net loss for 2025, driven by higher collaboration expenses, despite advancing its gene-editing pipeline and securing key approvals for CASGEVY.

CRISPR Therapeutics' 2024 10-K filing highlights the company's advancements in gene-based medicines, including the commercialization of CASGEVY and progress in CAR T and in vivo programs, while acknowledging ongoing financial losses and risks.

CRISPR Therapeutics AG's 10-K filing provides a comprehensive overview of its share structure, financial performance, and strategic direction, highlighting its advancements in gene editing technology.

Director Simeon George was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Ali Behbahani was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Maria Fardis was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Director Harold Edward Fleming was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director John Greene was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Director Katherine A. High was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

CRISPR Therapeutics AG has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 4, 2026, to vote on key corporate matters including financial statements, director elections, and compensation.

CRISPR Therapeutics has scheduled its 2025 Annual General Meeting for June 5, 2025, and is seeking shareholder votes on key proposals including the approval of financial statements, director elections, and executive compensation.

CRISPR Therapeutics announces its 2025 Annual General Meeting to be held on June 5, 2025, featuring proposals for board member re-elections, executive compensation approvals, and an increase in the maximum size of the Board of Directors.

CRISPR Therapeutics AG's upcoming Annual General Meeting on May 30, 2024, will address key proposals including financial approvals, board and committee elections, executive compensation, and amendments to equity plans and capital structure.

CRISPR Therapeutics announces its 2024 Annual General Meeting to be held on May 30, 2024, featuring proposals ranging from financial approvals to board member elections and compensation matters.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7,987,262 shares, representing 8.3% of the outstanding common stock of CRISPR Therapeutics AG.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.3% stake in CRISPR Therapeutics AG as of March 31, 2026.

Capital World Investors has disclosed a beneficial ownership of 5.1% in CRISPR Therapeutics AG, holding 4,929,428 shares.

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 11.79% of CRISPR Therapeutics AG's common stock as of March 31, 2026.

Orbis Investment Management Ltd. and Allan Gray Australia Pty Ltd. have disclosed a combined 6.2% beneficial ownership stake in CRISPR Therapeutics AG common stock.

Capital International Investors has filed an amended Schedule 13G, reporting a passive 1.2% beneficial ownership stake in CRISPR Therapeutics AG.